Axovant shares plunged after Hung abruptly resigned as CEO and also stepped down from his seat on the company board of directors. Source: BioSpace

A look at three drug approvals of vital importance to the company this year. Source: BioSpace

Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace

Nebula Genomic plans to offer inexpensive genetic testing, but allow the consumer to own their own genetic data. Source: BioSpace

ImmunoPrecise announces the appointment of Dr. Jennifer Bath, as the new President and CEO of the Company effective February 21, 2018. Source: BioSpace

Shares of Pieris have climbed more than 10 percent this morning after the company announced it inked a multi-program immuno-oncology collaboration with Seattle Genetics. Source: BioSpace

Less than two months into the year, Teva's new chief has already effectively written off a recovery for 2018. Source: BioSpace

Elastagen's revolutionary technology is based on recombinant human tropoelastin, the precursor of elastin which is a key component of youthful skin. Source: BioSpace

This biotech could potentially could be a better value. Source: BioSpace

It's start­ing to feel like Teva can't catch a break. Source: BioSpace